TY - JOUR
KW - Adolescent
KW - Adult
KW - Buprenorphine/therapeutic use
KW - Clinical Trials as Topic
KW - Humans
KW - Narcotic Antagonists/therapeutic use
KW - Opioid-Related Disorders/drug therapy
KW - Young Adult
AU - G. A. Subramaniam
AU - M. J. Fishman
AU - G. Woody
A1 - 
AB - Rising rates of opioid use among teenagers and young adults are a public health concern. Despite short durations of opioid use compared with those of adults, youth with opioid dependence have a host of co-occurring conditions, including polysubstance abuse, psychiatric disorders, hepatitis C infection, HIV risk, and high-risk sexual and criminal behaviors. Opioid-dependent youth typically are offered outpatient/residential treatment with brief detoxification, but one study showed that heroin users fare worse following residential treatment. Although abundant research supports the use of medication-assisted treatment for opioid-dependent adults, research is only recently emerging for youth. Buprenorphine, a partial opioid agonist, was proven safe and effective in improving abstinence from opioids in two controlled clinical trials. More research is needed to determine several clinically relevant areas: appropriate duration of agonist treatment, ways to enhance medication adherence, the value of integrated treatments for co-occurring conditions, and the role of opioid antagonists in opioid-dependent youth.
BT - Current psychiatry reports
C5 - Opioids & Substance Use
CP - 5
CY - United States
IS - 5
JF - Current psychiatry reports
N2 - Rising rates of opioid use among teenagers and young adults are a public health concern. Despite short durations of opioid use compared with those of adults, youth with opioid dependence have a host of co-occurring conditions, including polysubstance abuse, psychiatric disorders, hepatitis C infection, HIV risk, and high-risk sexual and criminal behaviors. Opioid-dependent youth typically are offered outpatient/residential treatment with brief detoxification, but one study showed that heroin users fare worse following residential treatment. Although abundant research supports the use of medication-assisted treatment for opioid-dependent adults, research is only recently emerging for youth. Buprenorphine, a partial opioid agonist, was proven safe and effective in improving abstinence from opioids in two controlled clinical trials. More research is needed to determine several clinically relevant areas: appropriate duration of agonist treatment, ways to enhance medication adherence, the value of integrated treatments for co-occurring conditions, and the role of opioid antagonists in opioid-dependent youth.
PP - United States
PY - 2009
SN - 1535-1645; 1523-3812
SP - 360
EP - 363
EP - 
T1 - Treatment of opioid-dependent adolescents and young adults with buprenorphine
T2 - Current psychiatry reports
TI - Treatment of opioid-dependent adolescents and young adults with buprenorphine
U1 - Opioids & Substance Use
U2 - 19785976
VL - 11
VO - 1535-1645; 1523-3812
Y1 - 2009
ER -